Eglin Pharmaceuticals' new oral drug EG-001 for the treatment of idiotic interstitiotic pneumonia has been officially approved by the FDA to enter Phase I clinical trials.

EG-001 is one of Eglin Pharmaceuticals' nine research and development pipelines for the treatment of idiopathic interstitial pneumonia (Idiopathic Interstitial Pneumonias, IIP).
IIP is a rare disease with unknown causes and similar clinical characteristics.
IIP can be divided into 6 sub-categories in histology, characterized by different degrees of inflammation of lung tissue and fibrosis of lung tissue.
clinical manifestations of IIP are gradual progress in breathing difficulties and lung imaging abnormalities.
no drugs in the world have been approved to treat IIP.
face of such a drug-free disease, the heavy use of glucoticoids is the only alternative therapy available to keep patients alive.
but long-term glucoticoid therapy is not only uncertain in efficacy, but also causes a series of side effects.
patients with advanced IIP can only rely on lung transplants to save lives.
EG-001 has high selective immunomodulation and anti-inflammatory effects.
tests have shown that EG-001 selectively activates a variety of anti-inflammatory genes, such as EnaC.
does not activate genes that produce side effects of glucosal hormones, such as FKBP5.
IIP worldwide in 2017 about 200,000 cases, including about 37,000 in the United States and about 57,000 in China.
the global IIP market size of about $4 billion.
the EG-001 IND approval is the second IND after Eglin's other drug of choice, EG-009, was approved for clinical use.
dates for the approval of the two are only 20 days apart.
, a fast-growing, innovative pharmaceutical company, began preparing for this IND filing last year.
like EG-009, it does a lot of layout for basic research and patent filings for idynogenic mesothotic pneumonia while preparing for clinical trials.
, CEO of Eglin Pharmaceuticals, said, "IIP is not only a global medical challenge, but also a huge gap in clinical needs.
focus on clinical needs, and focusing on drug value is something we've always believed in.
, we will make every effort to promote EG-001 clinical research, and strive to provide IIP patients with an effective treatment as soon as possible.
" About Eglin Pharmaceuticals Shenzhen Eglin Pharmaceutical Co., Ltd. ("Eglin") is a rapidly developing international biopharmaceutical company in the clinical stage, dedicated to the discovery and development of innovative drugs, as well as clinical research and development and commercialization worldwide.
's mission is to "focus on clinical needs and reach patients around the world", focusing on the development of innovative drugs in the areas of autoimmune, tumor immunity, and chronic diseases.
Eglin Pharmaceuticals adheres to a global and differentiated development strategy and actively develops new adaptations to existing drugs while exploring new targets.
, Drug Repurposing not only reduces research costs and accelerates research and development, but also increases the probability of success and the value of the drug.
Drug Repurposing is becoming a trend in the development of new drugs today, when the research and development cycle of new drugs is long and costly.
Eglin's corporate values of "closely focusing on clinical needs and accelerating innovative clinical development" and "abandoning the concept of corporate development that follows homogenization hotspots and focus on differentiated research and development" will continue to lead the future trend of the pharmaceutical industry with a "global perspective and a focus on pharmaceutical value".
Eglin upholds an open mind, vigorously promote independent research and development, but also actively promote strategic cooperation, in the world to seek cooperation opportunities, the introduction of high-quality products and first-class technology, in order to meet the urgent clinical needs of patients as soon as possible, to achieve enterprise value.
.